Bile acids as a “new hormone” in aging-related liver disease
Life Medicine · 29.09.2026 · 5 (5)
DOI: 10.1093/lifemedi/lnag030 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Life Medicine, online erschienen am 07.08.2026. Verfasst von Buyu Deng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Translational Medicine on Cell Fate and Disease, Shanghai Ninth People's Hospital, Key Laboratory of Cell Differentiation and Apoptosis…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Bile acids (BAs) have evolved from their classical definition as digestive surfactants to be recognized as potent endocrine signaling molecules that orchestrate systemic metabolism. Through activation of nuclear receptors, such as farnesoid X receptor (FXR), and membrane receptors, such as G protein-coupled BA receptor 1 (GPBAR1/TGR5), BAs regulate glucose, lipid, immune, and energy homeostasis. Aging reshapes BA synthesis, enterohepatic circulation, hydrophobicity, microbial biotransformation, and receptor responsiveness, thereby linking BA metabolism to hepatic senescence, inflammaging, and age-associated liver vulnerability. In turn, dysregulated BA signaling can amplify mitochondrial stress, endoplasmic reticulum stress, impaired autophagy, immune dysfunction, and senescence-associated secretory phenotypes, suggesting a bidirectional relationship between BA remodeling and aging progression. This review critically examines the role of BAs as hormone-like mediators within the aging liver microenvironment, summarizes major BA species and receptor preferences, integrates gut microbiota–BA crosstalk, and evaluates the therapeutic potential and caveats of targeting the BA–FXR–TGR5 axis in aging-related liver diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), autoimmune liver diseases (AILD), chronic hepatitis B (CHB), and hepatocellular carcinoma (HCC).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Translational Medicine on Cell Fate and Disease, Shanghai Ninth People's Hospital, Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education, Department of Pathophysiology, Sha…
- School of Exercise and Health, Shanghai University of Sport, Shanghai 200438, China.
- Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, PA 19111, United States.
- Nuclear Dynamics and Cancer Program, Fox Chase Cancer Center, Philadelphia, PA 19111, United States.
- Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA 19111, United States.
- Department of Orthopaedics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
ORCID-Profile: Ying Huang
Zitieren
APA
Deng, B., Li, X., Li, Y., Han, L., Zou, Z., Zhang, Y., Luo, J., Tang, X., Kong, H., Shi, C., Huang, Y., Luo, H., Fu, Y., & He, M. (2026). Bile acids as a “new hormone” in aging-related liver disease. Life Medicine, 5(5). https://doi.org/10.1093/lifemedi/lnag030
Vancouver
Deng B, Li X, Li Y, Han L, Zou Z, Zhang Y, et al. Bile acids as a “new hormone” in aging-related liver disease. Life Medicine. 2026;5(5). doi:10.1093/lifemedi/lnag030
BibTeX
@article{Deng2026,
author = {Deng, Buyu and Li, Xingjian and Li, Yue and Han, Longchuan and Zou, Zhihui and Zhang, Yingting and Luo, Jing and Tang, Xinxin and Kong, Hui and Shi, Chenxi and Huang, Ying and Luo, Hanzhi and Fu, Yinkun and He, Ming},
title = {Bile acids as a “new hormone” in aging-related liver disease},
journal = {Life Medicine},
year = {2026},
volume = {5},
number = {5},
doi = {10.1093/lifemedi/lnag030}
}
EUVIMED